Potential of a novel scaffold composed of human platelet lysate and fibrin for human corneal endothelial cells

Mishan, Mohammad Amir; Balagholi, Sahar; Chamani, Tahereh; Feizi, Sepehr; Soheili, Zahra‐Soheila; Rezaeikanavi, Mozhgan

doi:10.1007/s10561-021-09931-x

Cited by 5 publications

(6 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cell proliferation rates in the trilayer PCL and PCL‐fibrin cell‐cultured constructs were 34,900 and 46,000 cells per day, respectively. The fibrin cell carrier significantly improved cellular proliferation through efficient cell seeding and adhesion and enhanced cellular interaction in the PCL‐fibrin cell‐cultured constructs (Foroushani et al, 2021; Li et al, 2015; Mishan et al, 2022; Mol et al, 2005).…”

Section: Resultsmentioning

confidence: 99%

“…Fibrin increases the hydrophilicity of synthetic substrates, which improves cell adhesion and reduces cell loss during seeding but does not directly enhance cellular infiltration. Alternatively, fibrin cell carriers encapsulate cells and enable them to be dispersed throughout the substrate (Ahmed et al, 2015; Foroushani et al, 2021; Li et al, 2015; Mishan et al, 2022). For example, fibrin cell carriers have improved substrate cellularization in leaflet (Saidy et al, 2019) heart valve (Dijkman et al, 2012; Mol et al, 2005; Motta et al, 2019), corneal (Foroushani et al, 2021; Mishan et al, 2022), retinal (Soleimannejad et al, 2018), muscle (Liu et al, 2013), and bone (Chen et al, 2012) substrates for tissue engineering.…”

Section: Introductionmentioning

confidence: 99%

“…Alternatively, fibrin cell carriers encapsulate cells and enable them to be dispersed throughout the substrate (Ahmed et al, 2015; Foroushani et al, 2021; Li et al, 2015; Mishan et al, 2022). For example, fibrin cell carriers have improved substrate cellularization in leaflet (Saidy et al, 2019) heart valve (Dijkman et al, 2012; Mol et al, 2005; Motta et al, 2019), corneal (Foroushani et al, 2021; Mishan et al, 2022), retinal (Soleimannejad et al, 2018), muscle (Liu et al, 2013), and bone (Chen et al, 2012) substrates for tissue engineering. In all the above‐described tissue engineering cases, the fibrin gel was either the substrate itself or applied in randomly oriented substrates.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Fibrin gel enhanced trilayer structure in cell‐cultured constructs

Snyder

Jana

2023

Biotech & Bioengineering

View full text Add to dashboard Cite

Efficient cell seeding and subsequent support from a substrate ensure optimal cell growth and neotissue development during tissue engineering, including heart valve tissue engineering. Fibrin gel as a cell carrier may provide high cell seeding efficiency and adhesion property, improved cellular interaction, and structural support to enhance cellular growth in trilayer polycaprolactone (PCL) substrates that mimic the structure of native heart valve leaflets. This cell carrier gel coupled with a trilayer PCL substrate may enable the production of native-like cell-cultured leaflet constructs suitable for heart valve tissue engineering. In this study, we seeded valvular interstitial cells onto trilayer PCL substrates with fibrin gel as a cell carrier and cultured them for 1 month in vitro to determine if this gel can improve cell proliferation and production of extracellular matrix within the trilayer cell-cultured constructs. We observed that the fibrin gel enhanced cellular proliferation, their vimentin expression, and collagen and glycosaminoglycan production, leading to improved structure and mechanical properties of the developing PCL cell-cultured constructs. Fibrin gel as a cell carrier significantly improved the orientations of the cells and their produced tissue materials within trilayer PCL substrates that mimic the structure of native heart valve leaflets and, thus, may be highly beneficial for developing functional tissue-engineered leaflet constructs.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fibrin gel enhanced trilayer structure in cell‐cultured constructs

Snyder

Jana

2023

Biotech & Bioengineering

View full text Add to dashboard Cite

show abstract

“…More clinical data is needed to determine the role of endothelial cell therapy as well as possible variations in adjunct therapeutics-pharmacological and/or surgical-in Fuchs endothelial corneal dystrophy patients. www.co-ophthalmology.com gelatin, hydrogel, chitosan, agarose, and poly-elysine, as well as decellularized tissue such as human DM, corneal stroma, lens capsule, and posterior lamellae of the porcine or bovine cornea [31][32][33][34][35][36]. The techniques for implantation in animal models have been shown to be greatly similar to that of endothelial keratoplasty [33,37].…”

Section: Key Pointsmentioning

confidence: 99%

Current state of endothelial cell therapy

Koo

2024

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of review Currently, there is heightened interest surrounding endothelial cell therapy for the treatment of corneal edema. The purpose of this review article is to describe and summarize the background information as well as the research surrounding the emerging treatment modalities for endothelial cell therapy. Recent findings Marked advancements have been made in the translational research in this area, and increasing refinements have been demonstrated in the treatment protocols for cell therapy. Human clinical trials in this field are ongoing, specifically, in the area of injected human corneal endothelial cells (HCECs), with early results showing favorable safety and efficacy profiles. Summary Efficient and effective delivery of HCECs to patients with corneal edema and dysfunction now appears feasible, and the results from ongoing human clinical trials are much anticipated. Adjunct therapeutics—in the form of pharmacological agents and/or surgical techniques, such as descemetorhexis—will likely continue to play an important role in defining the future of endothelial cell therapy.

show abstract

“…A study comparing four types of electrospun nanofibre scaffolds found that blended polycaprolactone (PCL)/ collagen and PCL/gelatine were associated with significantly higher CEC viability compared with PCL alone, and PCL/chitosan [62]. HPL/fibrin scaffold has also been proposed [63]. Biological materials are an attractive option, being biocompatible, noncytotoxic, poorly immunogenic and noncarcinogenic [55].…”

Section: Corneal Endothelial Cell Delivery and Adhesionmentioning

confidence: 99%

Cell therapy in corneal endothelial disease

Wong

2022

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of reviewEndothelial keratoplasty is the current gold standard for treating corneal endothelial diseases, achieving excellent visual outcomes and rapid rehabilitation. There are, however, severe limitations to donor tissue supply and uneven access to surgical teams and facilities across the globe. Cell therapy is an exciting approach that has shown promising early results. Herein, we review the latest developments in cell therapy for corneal endothelial disease.Recent findingsWe highlight the work of several groups that have reported successful functional outcomes of cell therapy in animal models, with the utilization of human embryonic stem cells, human-induced pluripotent stem cells and cadaveric human corneal endothelial cells (CECs) to generate populations of CECs for intracameral injection. The use of corneal endothelial progenitors, viability of cryopreserved cells and efficacy of simple noncultured cells, in treating corneal decompensation is of particular interest. Further additions to the collective understanding of CEC physiology, and the process of cultivating and administering effective cell therapy are reviewed as well.SummaryThe latest developments in cell therapy for corneal endothelial disease are presented. The continuous growth in this field gives rise to the hope that a viable solution to the large numbers of corneal blind around the world will one day be reality.

show abstract

Potential of a novel scaffold composed of human platelet lysate and fibrin for human corneal endothelial cells

Cited by 5 publications

References 76 publications

Fibrin gel enhanced trilayer structure in cell‐cultured constructs

Fibrin gel enhanced trilayer structure in cell‐cultured constructs

Current state of endothelial cell therapy

Cell therapy in corneal endothelial disease

Contact Info

Product

Resources

About